These treatments do more than slim your waist
Empower tripled its revenue during the GLP-1 shortage, from $119 million in 2022 to $377 million in 2024, according to figures they shared with the Houston Business Journal
Similarly, dual brands often address different levels of disease burden and unmet needs associated with different patient conditions or prevalence
The most common nociplastic pain syndromes are chronic widespread pain, fibromyalgia, chronic low back pain of unknown causes, chronic visceral pain syndromes and others
Combining the results of both hippocampi allowed us to efficiently distinguish the patients from the healthy older people, says Mandal
KPV is a tripeptide that comes from the naturally occurring hormone alpha-MSH